Member Info for Dazpink

https://www.***************************/puretech-health-plc-prtc-stock-analysis-a-biotech-firm-with-skyrocketing-revenue-growth/4121246896

puretech health plc represents a unique opportunity for investors interested in cutting-edge healthcare solutions. while the company’s financial metrics may not appeal to traditional value investors, those with a focus on high-growth potential in the biotech sector might find puretech’s innovative pipeline and significant revenue growth compelling. as with any investment, understanding the nuances of the company’s operations and continuous developments in its clinical trials will be key to making informed investment decisions.

Amazing, back in 2024 Terns Pharmaceuticals appointed a new chief business officer Melita Sun Jung , done a great deal sold it for billions

Merck & Co tabling a $6.7bn acquisition.

Puretech will be sold, my feeling is later this year

Why not keep ownership of the entities in full, PureTech Founded Entity Karuna Therapeutics sold it to Bristol Myers Squibb for $14 Billion in 2023 and receive peanuts in return for what it could have had.

Same thing with Seaport Therapeutics, it could have put its own money into it instead of now owning approximately 35.1% of the company on a partially diluted basis. It will be sold soon an again loses millions or billions

Change in strategy with Celea Therapeutics, 100%is owned but having to pursue third party investors to fund phase 3

Pattern of buying in batches of £10k, £12k and £15k possibly from the same buyer

Large buy late yesterday which hasn’t happened for a while, could we finally receive some positive news this week that changes things

Company now worth less than cash in bank, just saying

Agree tuscany1, I also listened to the presentation, great detail on hubs and pipeline that has potential.

Nothing on actual numbers or addressing downward company value

Seems to that if this keeps going towards £1.10 region it is a prime potential target for acquisition, 78% of its shares held by institutions which will want returns sooner rather than in years to come

This week would be nice to hear further updates

Estonian Commercialisation Status as per AI,

* Operational Readiness: The company is finalising the framework with Cellin Technologies to supply HG-CT-1 under Estonia's hospital exemption pathway.

* Revenue Potential: This initiative remains the company's primary target for near-term revenue, with treatment costs potentially reimbursed by the Estonian National Health Fund

Recent Transactions are encourging

https://leerink.com/sector/biopharma/

8 years, investors have been shafted for a long time, the old CEO and the board had failed to understand how this company should have been run hence both not involved in the current decision making.

Looking at the latest presentation and milestones in 2026, good times are on the horizon I am sure the tide is turning.

I am backing Analysts who have a highly bullish outlook on PureTech Health (LSE: PRTC), with a consensus "Buy" rating and a 12-month share price target around 504p–518p GBX

Don’t worry about current share price unless you are planning to bail out, this will rocket very soon once we have updates on funding for Celea Therapeutic and the first patient lined up for LYT-100

Gallop Oncology Will then be another icing on the cake

Interesting, I asked last week if Dave Smith was going to increase his holding this week, bingo he does now owns 10.2% follow the money

2026 will see a surge in drug development with the announcement from the FDA that the default position will be to require one study for hew drugs and other health products

Going forward the FDA Will Require Only 1 Study to Approve New Drugs, Speeding Up the old Process.

Puretech will benefit hugely this year from this change

https://www.ajmc.com/view/fda-will-require-only-1-study-to-approve-new-drugs-speeding-up-process#:~:text=The%20commentary%20announced%20that%20the,be%20approved%20for%20use%20nationwide.

2026 will see a surge in drug development with the announcement from the FDA that the default position will be to require one study for hew drugs and other health products

Going forward the FDA Will Require Only 1 Study to Approve New Drugs, Speeding Up the old Process.

Hemo will benefit hugely this year from this change

https://www.ajmc.com/view/fda-will-require-only-1-study-to-approve-new-drugs-speeding-up-process#:~:text=The%20commentary%20announced%20that%20the,be%20approved%20for%20use%20nationwide.

Morning pumpky, only jesting not a scooby doo on what percentage we hullers own. Dave Smith from Grimsby owns 7.76% wonder if he will purchase more early next week

We are now at a pivotal point in hemo history which is bloody marvelous

The city of hull own half the company ant they know it works.

I agree, yes we do in hull

Oops missed it, it is on the slide, things coming together nicely

Great to see Received Orphan Drug designation & Fast Track designation for both LYT-200 & LYT-100

Strange that Orphan Drug Designation for LYT-100 is not shown on the presentation slides for Celea Therapeutics

Great news

Key Benefits of Orphan Drug Designation

Obtaining ODD provides several key advantages that act as a "game-changer" for developers, particularly smaller companies:

Market Exclusivity: Upon approval, the drug receives a period of protection from competition (7 years in the US, 10 years in the EU), providing a significant commercial advantage.

Reduced Regulatory Fees: Developers receive exemptions or waivers from significant fees, such as the Prescription Drug User Fee Act (PDUFA) fees in the US, which can save millions of dollars.

Tax Credits: In the US, sponsors can claim up to 25% to 50% tax credits on qualified clinical trial expenses.

Scientific Assistance: Companies get access to specialized regulatory advice (protocol assistance) from the EMA or FDA to help design efficient trials for small populations.

Increased Visibility: It signals to investors and partners that the program has validated potential, increasing the ability to raise capital.